Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive...

σε πρόσθεσε στο Health

2025-09-23 07:22:55 - Μετάφραση

Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List Price

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...

0 Σχόλια 0 Μοιράστηκε 271 Views 0 Προεπισκόπηση